ACVRL1 and neoplasm: Also, the clinical results of ascrinvacumab (PF-03446962), a moAb against activin receptor-like kinase-1 (ALK1), a type I subclass of the TGF-β receptor with dose-dependent anti-angiogenic activity, have been disappointing in various tumor types [47,48].